<DOC>
	<DOC>NCT00073307</DOC>
	<brief_summary>The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who have received one prior systemic regimen for advanced disease.</brief_summary>
	<brief_title>Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer</brief_title>
	<detailed_description>Overall Survival (OS), Patient-reported outcome (PRO)</detailed_description>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients with unresectable and/or metastatic, measurable renal cell carcinoma histologically or cytologically documented Patients must have had one prior systemic therapy for advanced disease, which was completed at least 30 days but no longer than 8 months prior to randomization Patients who have at least one unidimensional measurable lesion by CTscan or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) Patients who have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Patients who have adequate coagulation, liver and kidney functions Patients with rare subtypes of renal cell carcinoma (RCC) such as pure papillary cell tumors, mixed tumor containing predominantly sarcomatoid cells, Bellini carcinoma, medullary carcinoma, or chromophobe oncocytic tumors Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma,or superficial bladder tumors, or other malignancies curatively treated &gt; 2 years prior to entry Cardiac arrhythmias requiring antiarrhythmics, symptomatic coronary artery disease or ischemia or congestive heart failure Patients with a history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C Patients with a history or presence of metastatic brain or meningeal tumors Patients with seizure disorder requiring medication (such as antiepileptics) History of organ allograft or bone marrow transplant of stem cell rescue Patients who are pregnant or breastfeeding Women of childbearing potential must have a negative pregnancy test prior to drug administration. Both men and women enrolled in this trial must use adequate birth control Patients who have three or more of the following: ECOG performance status greater than or equal to 2, Abnormally high lactate dehydrogenase, Abnormally high serum hemoglobin, Abnormally high corrected serum calcium, Absence of prior nephrectomy Excluded therapies and medications, previous and concomitant: Concurrent anticancer chemotherapy, immunotherapy or hormonal therapy except biphosphonates Significant surgery with 4 weeks of start of study Investigational drug therapy during or within 30 days Concomitant treatment with rifampin or St. John's Wort Prior use of Rafkinase inhibitors (RKI), MEK or Farnesyl transferase inhibitors Prior use of Bevacizumab, and all other drugs (investigational or licensed) that target VEGF/VEGF receptors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Renal Cell Cancer (RCC)</keyword>
	<keyword>Cancer</keyword>
</DOC>